| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Fulcrum Therapeutics, Inc. (FULC) has 10 insiders with recent SEC Form 4 filings, including 5 buys and 11 sells. FULC is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| 10% | 8.85M | $33.37M | - | |
| Dir | 469.9K | $1.77M | - | |
| Dir | 36.0K | $135.7K | - | |
| Dir | 36.0K | $135.7K | - | |
| Dir | 36.0K | $135.7K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| May 11, 2020 | Thomson Peter G. | VP Finance &Accounting | Sell | 7,500 | $16.00 | $120,000.00 | -26.3% | |
| Mar 2, 2020 | Cadavid Diego | SVP Clinical Development | Sell | 2,143 | $17.38 | $37,254.78 | -1.6% | |
| Feb 24, 2020 | Thomson Peter G. | VP Finance &Accounting | Sell | 5,000 | $16.83 | $84,152.88 | -5.4% | |
| Feb 19, 2020 | Gould Robert J85 | See Remarks | Sell | 2,500 | $20.00 | $50,000.00 | -0.4% | |
| Feb 19, 2020 | Wallace Owen B. | Chief Scientific Officer | Sale+OE | 6,088 | $20.00 | $121,760.00 | -4.6% | |
| Feb 3, 2020 | Cadavid Diego | SVP Clinical Development | Sell | 2,143 | $17.33 | $37,141.83 | -3.0% | |
| Jan 23, 2020 | Thomson Peter G. | VP Finance &Accounting | Sell | 5,000 | $17.22 | $86,101.96 | -6.9% | |
| Jul 22, 2019 | Third Rock Ventures Iv, L.P.69 | 10% Owner | Buy | 81,250 | $16.00 | $1,300,000.00 | +3.6% | |
| Jul 22, 2019 | Third Rock Ventures Iii, L.P.65 | 10% Owner | Buy | 81,250 | $16.00 | $1,300,000.00 | +1.4% | |
| Jul 22, 2019 | Casdin Capital, LLC97 | 10% Owner | Buy | 140,000 | $15.84 | $2,217,495.00 | +8.5% |